Adaptive Biotechnologies Corp (ADPT): A Technical Analysis

ADPT has 36-month beta value of 1.24. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for ADPT is 138.51M, and currently, short sellers hold a 6.11% ratio of that float. The average trading volume of ADPT on April 03, 2024 was 1.45M shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

ADPT) stock’s latest price update

The stock of Adaptive Biotechnologies Corp (NASDAQ: ADPT) has decreased by -8.05 when compared to last closing price of 2.98.Despite this, the company has seen a loss of -4.86% in its stock price over the last five trading days. InvestorPlace reported 2024-03-27 that This month in March is a great time to pick up shares in these best penny stocks to buy. I chose the companies due to their strong fundamentals and potential for significant upside.

ADPT’s Market Performance

Adaptive Biotechnologies Corp (ADPT) has seen a -4.86% fall in stock performance for the week, with a -31.33% decline in the past month and a -42.56% plunge in the past quarter. The volatility ratio for the week is 9.15%, and the volatility levels for the past 30 days are at 7.86% for ADPT. The simple moving average for the past 20 days is -17.42% for ADPT’s stock, with a -46.66% simple moving average for the past 200 days.

Analysts’ Opinion of ADPT

Many brokerage firms have already submitted their reports for ADPT stocks, with JP Morgan repeating the rating for ADPT by listing it as a “Overweight.” The predicted price for ADPT in the upcoming period, according to JP Morgan is $15 based on the research report published on July 05, 2023 of the previous year 2023.

Scotiabank, on the other hand, stated in their research note that they expect to see ADPT reach a price target of $15. The rating they have provided for ADPT stocks is “Sector Outperform” according to the report published on January 05th, 2023.

Piper Sandler gave a rating of “Overweight” to ADPT, setting the target price at $14 in the report published on December 21st of the previous year.

ADPT Trading at -25.56% from the 50-Day Moving Average

After a stumble in the market that brought ADPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.82% of loss for the given period.

Volatility was left at 7.86%, however, over the last 30 days, the volatility rate increased by 9.15%, as shares sank -26.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.08% lower at present.

During the last 5 trading sessions, ADPT fell by -2.95%, which changed the moving average for the period of 200-days by -67.76% in comparison to the 20-day moving average, which settled at $3.27. In addition, Adaptive Biotechnologies Corp saw -44.08% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ADPT starting from ROBINS CHAD M, who sale 48,673 shares at the price of $3.43 back on Mar 05 ’24. After this action, ROBINS CHAD M now owns 2,576,701 shares of Adaptive Biotechnologies Corp, valued at $167,007 using the latest closing price.

RUBINSTEIN JULIE, the President of Adaptive Biotechnologies Corp, sale 39,070 shares at $3.47 during a trade that took place back on Mar 05 ’24, which means that RUBINSTEIN JULIE is holding 472,754 shares at $135,764 based on the most recent closing price.

Stock Fundamentals for ADPT

Current profitability levels for the company are sitting at:

  • -1.18 for the present operating margin
  • 0.52 for the gross margin

The net margin for Adaptive Biotechnologies Corp stands at -1.35. The total capital return value is set at -0.35. Equity return is now at value -58.31, with -29.68 for asset returns.

Based on Adaptive Biotechnologies Corp (ADPT), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -1.12. The debt to equity ratio resting at 0.45. The interest coverage ratio of the stock is -31.04.

Currently, EBITDA for the company is -179.38 million with net debt to EBITDA at -0.92. When we switch over and look at the enterprise to sales, we see a ratio of 3.31. The receivables turnover for the company is 4.37for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.66.

Conclusion

To put it simply, Adaptive Biotechnologies Corp (ADPT) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts